Evidence for a bimodal relation between serum lysozyme and prognosis in 232 patients with acute myeloid leukaemia

European Journal of Haematology

Volumn 70, Issue 1, 2003, Pages 26-33

  Åström, Maria ^a,b   Bodin, Lennart ^a   Hörnsten, Per ^c   Wahlin, Anders ^c   Tidefelt, Ulf ^a,b  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute myeloid leukaemia; CD14; Lysozyme; Monocyte; Prognosis; Renal failure

Indexed keywords

AMSACRINE; ANTHRACYCLINE DERIVATIVE; ANTHRAQUINONE; CYTARABINE; ETOPOSIDE; LYSOZYME;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HAZARD ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SURVIVAL;

ACUTE DISEASE; AGED; BIOLOGICAL MARKERS; ENZYME TESTS; FEMALE; HUMANS; KIDNEY FAILURE; KIDNEY FUNCTION TESTS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MURAMIDASE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 12244280003     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2003.02780.x     Document Type: Article

References (50)

1. CHIPMAN DM, SHARON N. Mechanism of lysozyme action. Science 1969;165:454-465.
2. LEVY O. Antibiotic proteins of polymorphonuclear leukocytes. Eur J Haematol 1996;56:263-277.
3. OSSERMAN EF, KLOCKARS M, HALPER J, FISCHEL RE. Effects of lysozyme on normal and transformed mammalian cells. Nature 1973;243:331-335.
4. LEMARBRE P, RINEHART JJ, KAY NE, VESELLA R, JACOB HS. Lysozyme enhances monocyte-mediated tumoricidal activity, a potential amplifying mechanism of tumor killing. Blood 1981;58:994-999.
5. YABE N, KOMIYA K, TAKEZONO T, MATSUI H. Lysozyme as a regulator of interleukin-2-activated lymphocyte proliferation. In Vitro Cell Dev Biol Anim 1993;29A:795-806.
6. SAVA G, PACOR S, DASIC G, BERGAMO A. Lysozyme stimulates lymphocyte response to ConA and IL-2 and potentiates 5-fluorouracil action on advanced carcinomas. Anticancer Res 1995;15:1883-1888.
7. SAVA G. Pharmacological aspects and therapeutic applications of lysozymes. In: JOLLES, P, ed. Lysozymes: Model Enzymes in Biochemistry and Biology. Basel: Birkhäuser, 1996: 433-449.
8. REITAMO S, KLOCKARS M, ADINOLFI M, OSSERMAN EF. Human lysozyme (origin and distribution in health and disease). Ric Clin Lab 1978;8:211-231.
9. LOLLIKE K, KJELDSEN L, SENGELOV H, BORREGAARD N. Lysozyme in human neutrophils and plasma. A parameter of myelopoietic activity. Leukemia 1995;9:159-164.
10. MALMQUIST J. Serum and urinary lysozyme in leukaemia and polycythaemia vera. Scand J Haematol 1972;9:258-266.
11. HANSEN NE. Lysozyme activity in leukemia. In: Plasma Lysozyme - a Measure of Neutrophil Turnover. An analytical review. Copenhagen: Munksgaard, 1974; 7: 70-87.
12. OBERG G, DAHL R, ELLEGAARD J, SUNDSTROM C, VAETH M, VENGE P. Diagnostic and prognostic significance of serum measurements of lactoferrin, lysozyme and myeloperoxidase in acute myeloid leukemia (AML): recognition of a new variant, high-lactoferrin AML. Eur J Haematol 1987;38:148-155.
13. SEXTON C, BUSS D, POWELL B, et al. Usefulness and limitations of serum and urine lysozyme levels in the classification of acute myeloid leukemia: an analysis of 208 cases. Leuk Res 1996;20:467-472.
14. BENNETT JM, CATOVSKY D, DANIEL MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620-625.
15. BRUNNING RD, MATUTES E, HARRIS NL, et al. Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2001: 75-107.
16. WIERNIK PH, SERPICK AA. Clinical significance of serum and urinary muramidase activity in leukemia and other hematologic malignancies. Am J Med 1969;46:330-343.
17. CURRIE G. Prognostic significance of serum lysozyme in adult acute myelogenous leukaemia. Lancet 1976;1:835-837.
18. SCOTT CS, STARK AN, LIMBERT HJ, MASTER PS, HEAD C, ROBERTS BE. Diagnostic and prognostic factors in acute monocytic leukaemia: an analysis of 51 cases. Br J Haematol 1988;69:247-252.
19. HOYLE CF, GRAY RG, WHEATLEY K, et al. Prognostic importance of Sudan Black positivity: a study of bone marrow slides from 1386 patients with de novo acute myeloid leukaemia. Br J Haematol 1991;79:398-407.
20. PRUZANSKI W, WILSON DR. Renal handling of endogenous lysozyme in man. J Lab Clin Med 1977;90:61-67.
21. TOBELEM G, JACQUILLAT C, CHASTANG C, et al. Acute monoblastic leukemia: a clinical and biologic study of 74 cases. Blood 1980;55:71-76.
22. KEATING MJ, SMITH TL, GEHAN EA, MCCREDIE KB, BODEY GP, FREIREICH EJ. A prognostic factor analysis for use in development of predictive models for response in adult acute leukemia. Cancer 1982;50:457-465.
23. MAACK T, HYUNG PARK C, CAMARGO MJF. Renal filtration, transport, and metabolism of proteins. In: SELDIN, DW, GIEBISCH, G, eds. The Kidney: Physiology and Pathophysiology. New York: Raven Press, 1985: 1773-1803.
24. PERAZELLA MA, EISEN RN, FREDERICK WG, BROWN E. Renal failure and severe hypokalemia associated with acute myelomonocytic leukemia. Am J Kidney Dis 1993,22:462-467.
25. MUNKER R, HILL U, JEHN U, KOLB HJ, SCHALHORN A. Renal complications in acute leukemias. Haematologica 1998;83:416-421.
26. ASTROM M, BODIN L, NILSSON I, TIDEFELT U. Treatment, long-term outcome and prognostic variables in 214 unselected AML patients in Sweden. Br J Cancer 2000;82:1387-1392.
27. WAHLIN A, MARKEVARN B, GOLOVLEVA I, NILSSON M. Improved outcome in adult acute myeloid leukaemia is almost entirely restricted to young patients and associated with stem cell transplantation. Eur J Haematol 2002;68:54-63.
28. WHEATLEY K, BURNETT AK, GOLDSTONE AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999; 107:69-79.
29. PARRY JR RM, CHANDAN RC, SHAHANI KM. A rapid and sensitive assay of muramidase. Proc Soc Exp Biol Medical 1965;119:384-386.
30. BROCHNER-MORTENSEN J, JENSEN S, RODBRO P. Delimitation of plasma creatinine concentration values for assessment of relative renal function in adult patients. Scand J Urol Nephrol 1977;11:257-262.
31. JELLIFFE RW. Creatinine clearance: bedside estimate. Ann Intern Med 1973;79:604-605.
32. GRAMBSCH PM, THERNEAU TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-526.
33. ESTEY EH. Prognostic factors in acute myelogenous leukemia. Leukemia 2001;15:670-672.
34. STARK AN, THOROGOOD J, HEAD C, ROBERTS BE, SCOTT CS. Prognostic factors and survival in chronic myelomonocytic leukaemia (CMML). Br J Cancer 1987;56:59-63.
35. DEL POETA G, STASI R, VENDITTI A, et al. Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia 1994;8:388-394.
36. FERGEDAL M, ASTROM M, TIDEFELT U, KARLSSON MG. Differences in CD14 and α-naphthyl acetate esterase positivity and relation to prognosis in AML. Leuk Res 1998;22:25-30.
37. NORGAARD JM, OLESEN LH, OLESEN G, et al. FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia. Eur J Haematol 2001;67:221-229.
38. HANSEN NE. Lysozyme assay. In: Plasma Lysozyme - a Measure of Neutrophil Turnover. An analytical review. Copenhagen: Munksgaard 1974; 7: 14-21.
39. KATZ MH. Assumptions of multiple linear regression, multiple logistic regression, and proportional hazards analysis. In: Multivariable Analysis: a Practical Guide for Clinicians. Cambridge: Cambridge University Press, 1999: 36-54.
40. LUBBERT M, MERTELSMANN R, HERRMANN F. Cytosine methylation changes during normal hematopoiesis and in acute myeloid leukemia. Leukemia 1997;11:S12-S18.
41. KARLE H, HANSEN NE, KILLMANN SA. Intracellular lysozyme in mature neutrophils and blast cells in acute leukemia. Blood 1974;44:247-255.
42. KLOCKARS M, ROBERTS P. Stimulation of phagocytosis by human lysozyme. Acta Haematol 1976;55:289-295.
43. GORDON LI, DOUGLAS SD, KAY NE, YAMADA O, OSSERMAN EF, JACOB HS. Modulation of neutrophil function by lysozyme. Potential negative feedback system of inflammation. J Clin Invest 1979;64:226-232.
44. TANIDA N, OHNO N, ADACHI Y, et al. Modification of immunopharmacological activities of synthetic monosaccharide lipid A analogue, GLA60, by lysozyme. J Biochem (Tokyo) 1992;112:616-623.
45. SUGAHARA T, MURAKAMI F, YAMADA Y, SASAKI T. The mode of actions of lysozyme as an immunoglobulin production stimulating factor. Biochim Biophys Acta 2000;1475:27-34.
46. SAVA G, CESCHIA V, PACOR S, ZABUCCHI G. Observations on the antimetastatic action of lysozyme in mice bearing Lewis lung carcinoma. Anticancer Res 1991;11:1109-1113.
47. DAS S, BANERJEE S, GUPTA JD. Experimental evaluation of preventive and therapeutic potentials of lysozyme. Chemotherapy 1992;38:350-357.
48. RINEHART JJ, CERILLI JG, JACOB HS, OSSERMAN EF. Lysozyme stimulates lymphocyte proliferation in monocyte-depleted mixed lymphocyte cultures. J Lab Clin Med 1982;99:370-381.
49. SIWICKI AK, KLEIN P, KICZKA W, et al. In vitro modulating effects of monomer and dimerized lysozyme on polymorphonuclear (PMN) and mononuclear (MN) cell activity. In: STOLEN, JS, FLETCHER, TC, BAYNE, CJ, SECOMBES, CJ, eds. Modulators of Immune Responses. The Evolutionary Trail. Fair Haven, NJ (USA): Beckenridge Series, Vol. 2. Place: SOS Publications, 1996: 221-231.
50. MORAND M, SIWICKI A, POZET F, KLEIN P, VINAIZE JC, KECK N. Effects of dimerized lysozyme (KLP-602) on the cellular and humoral defence mechanisms in sheatfish (Silurus glanis): in vitro and in vivo study. Vet Res 1999; 30:411-418.